Physician profile
Kurt Kampert
NPI 1801889258
$1,759.10
in general payments reported to CMS, 2019-2025
11 companies · $90.95 in 2025
The $90.95 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $56.14 · 2021: $279 · 2022: $293 · 2023: $570 · 2024: $332 · 2025: $90.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $951.46 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Novartis Pharmaceuticals Corporation | $281.05 | 2019-2025 | |
| Pfizer INC. | $261.61 | 2020-2023 | |
| Glaxosmithkline, LLC. | $126.76 | 2023-2024 | Benlysta |
| Ucb, INC. | $35.52 | 2019-2020 | |
| Welch Allyn | $24.97 | 2021 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $16.16 | 2021 | |
| Lilly USA, LLC | $15.78 | 2022 | |
| Horizon Therapeutics Plc | $13.06 | 2020 | |
| Abbvie INC. | $13.04 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Kampert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.